. Position 119 (highlighted in green) had not been previously implicated in CG sensitivity, but is identified as a candidate permissive substitution in subsequent analyses. (B) Viability of homozygous first instar larvae, pupae and adults for the first series of engineered substitution lines. Dots indicate identity with the ancestral reference at sites C104, Q111, and N122. Plotted is the proportion of surviving homozygous mutant offspring (i.e. EYFP-), scaled by the proportion for the wild-type control. The number of individuals assayed is indicated in each case. Survival odds relative to the wild type-strain (. . .) was tested using a Fisher's Exact Test, with adjusted P-values indicated as: ***p<0.001; **p<0.01, *p<0.05. All larvae to pupa survivorship are significantly lower than wild-type (p<1e-5) except for Q111V. All larvae to adult survivorship are significantly lower than wild-type (p<1e-5 
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∆ Figure 1 -figure supplement 1. Engineering strategy for generating amino acid substitution lines. A targeted replacement of exons 2-6b with a mini-white gene was generated by ends-out homologous recombination. The mini-white gene was removed using Cre-lox site-specific recombination to create the D2-6b 'Founder line'. The founder line is injected with the PGE-ATPa plasmid carrying a substitution of choice (asterisk) and incorporated by site-specific phiC31/attP integration. The mini-white gene was removed using Cre-lox site-specific recombination to create engineered ATPa (ATPalpha) lines (Supplementary file 1). DOI: https://doi.org/10.7554/eLife.48224.003 
